# Martin R J Kolb

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 238 papers | 19,493 citations | 20817 60 h-index | 12272 133 g-index |
| 244 all docs | 244 docs citations | 244 times ranked | 15972 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2071-2082. | 27.0 | 3,351 |
| 2 | Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2019, 381, 1718-1727. | 27.0 | 1,338 |
| 3 | Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275. | 5.6 | 1,006 |
| 4 | The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. International Journal of Biochemistry and Cell Biology, 2008, 40, 362-382. | 2.8 | 781 |
| 5 | Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1434-1445. | 6.7 | 667 |
| 6 | Transient expression of IL-1Î² induces acute lung injury and chronic repair leading to pulmonary fibrosis. Journal of Clinical Investigation, 2001, 107, 1529-1536. | 8.2 | 655 |
| 7 | Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 588-594. | 5.6 | 486 |
| 8 | Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28. | 3.2 | 458 |
| 9 | Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF-Î²-Mediated Pulmonary Fibrosis. Journal of Immunology, 2004, 173, 2099-2108. | 0.8 | 349 |
| 10 | Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€"subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine,the, 2020, 8, 453-460. | 10.7 | 331 |
| 11 | An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 667-679. | 2.9 | 267 |
| 12 | Progressive Transforming Growth Factor Î²1â€"induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 889-898. | 5.6 | 237 |
| 13 | TGF-Î² and Smad3 Signaling Link Inflammation to Chronic Fibrogenesis. Journal of Immunology, 2005, 175, 5390-5395. | 0.8 | 227 |
| 14 | What's in a name? That which we call IPF, by any other name would act the same. European Respiratory Journal, 2018, 51, 1800692. | 6.7 | 226 |
| 15 | Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0151425. | 2.5 | 223 |
| 16 | Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731. | 27.0 | 207 |
| 17 | Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 1-15. | 2.9 | 199 |
| 18 | Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax, 2017, 72, 340-346. | 5.6 | 191 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 381-389. | 10.7 | 189 |
| 20 | Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980. | 10.7 | 185 |
| 21 | VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. Journal of Clinical Investigation, 2009, 119, 1298-1311. | 8.2 | 184 |
| 22 | Gene Transfer of Transforming Growth Factor-Î²1 to the Rat Peritoneum. Journal of the American Society of Nephrology: JASN, 2001, 12, 2029-2039. | 6.1 | 184 |
| 23 | Transient Transgene Expression of Decorin in the Lung Reduces the Fibrotic Response to Bleomycin. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 770-777. | 5.6 | 172 |
| 24 | Stretch-induced Activation of Transforming Growth Factor-Î²<sub>1</sub> in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 84-96. | 5.6 | 165 |
| 25 | Matrix abnormalities in pulmonary fibrosis. European Respiratory Review, 2018, 27, 180033. | 7.1 | 165 |
| 26 | Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2019, 54, 1900161. | 6.7 | 164 |
| 27 | Differences in the Fibrogenic Response after Transfer of Active Transforming Growth Factor-Î²1 Gene to Lungs of â€œFibrosis-proneâ€•and â€œFibrosis-resistantâ€•Mouse Strains. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 141-150. | 2.9 | 161 |
| 28 | Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis. Current Pharmaceutical Design, 2003, 9, 39-49. | 1.9 | 151 |
| 29 | The natural history of progressive fibrosing interstitial lung diseases. Respiratory Research, 2019, 20, 57. | 3.6 | 151 |
| 30 | Progressive pulmonary fibrosis is mediated by TGF-Î² isoform 1 but not TGF-Î²3. International Journal of Biochemistry and Cell Biology, 2008, 40, 484-495. | 2.8 | 148 |
| 31 | Connective Tissue Growth Factor Is Crucial to Inducing a Profibrotic Environment in â€œFibrosis-Resistantâ€•Balb/c Mouse Lungs. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 510-516. | 2.9 | 142 |
| 32 | Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. European Respiratory Journal, 2016, 48, 187-195. | 6.7 | 130 |
| 33 | Inflammatory Cytokines, Angiogenesis, and Fibrosis in the Rat Peritoneum. American Journal of Pathology, 2002, 160, 2285-2294. | 3.8 | 123 |
| 34 | Adenoviral Gene Transfer of Connective Tissue Growth Factor in the Lung Induces Transient Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 770-778. | 5.6 | 121 |
| 35 | TGF-Î²1 Induces Progressive Pleural Scarring and Subpleural Fibrosis. Journal of Immunology, 2007, 179, 6043-6051. | 0.8 | 114 |
| 36 | Antiangiogenic and Antifibrotic Gene Therapy in a Chronic Infusion Model of Peritoneal Dialysis in Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 721-728. | 6.1 | 112 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Acute exacerbations of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180071. | 7.1 | 109 |
| 38 | Idiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers - Insights from the Bench Side. Respiration, 2013, 86, 441-452. | 2.6 | 108 |
| 39 | First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity ofÂâ‰50Â% of Predicted Value. Lung, 2016, 194, 739-743. | 3.3 | 102 |
| 40 | Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. ELife, 2018, 7, . | 6.0 | 99 |
| 41 | Angiogenesis in Pulmonary Fibrosis. Chest, 2012, 142, 200-207. | 0.8 | 98 |
| 42 | Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal, 2018, 51, 1702133. | 6.7 | 98 |
| 43 | Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. FASEB Journal, 2013, 27, 1549-1560. | 0.5 | 95 |
| 44 | miR-92a regulates TGF-Î²1-induced WISP1 expression in pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2014, 53, 432-441. | 2.8 | 95 |
| 45 | Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 131, 49-57. | 2.9 | 92 |
| 46 | Cardiopulmonary Exercise Testing to Detect Chronic Thromboembolic Pulmonary Hypertension in Patients with Normal Echocardiography. Respiration, 2014, 87, 379-387. | 2.6 | 89 |
| 47 | Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. Kidney International, 2010, 77, 319-328. | 5.2 | 87 |
| 48 | Design of the INPULSISâ„¢ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2014, 108, 1023-1030. | 2.9 | 82 |
| 49 | The importance of interventional timing in the bleomycin model of pulmonary fibrosis. European Respiratory Journal, 2020, 55, 1901105. | 6.7 | 82 |
| 50 | Fibroblast growth factor-1 attenuates TGF-Î²1-induced lung fibrosis. Journal of Pathology, 2016, 240, 197-210. | 4.5 | 81 |
| 51 | Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow. European Respiratory Journal, 2020, 56, 2003147. | 6.7 | 81 |
| 52 | Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936. | 6.7 | 75 |
| 53 | Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Scientific Reports, 2017, 7, 13281. | 3.3 | 73 |
| 54 | Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800663. | 6.7 | 73 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Local Delivery of GM-CSF Protects Mice from Lethal Pneumococcal Pneumonia. Journal of Immunology, 2011, 187, 5346-5356. | 0.8 | 72 |
| 56 | M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. Journal of Leukocyte Biology, 2017, 101, 285-295. | 3.3 | 72 |
| 57 | Oxidative stress contributes to the induction and persistence of TGF-Î²1 induced pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2011, 43, 1122-1133. | 2.8 | 71 |
| 58 | Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin. Thorax, 2015, 70, 636-646. | 5.6 | 71 |
| 59 | Staging of idiopathic pulmonary fibrosis: past, present and future. European Respiratory Review, 2014, 23, 220-224. | 7.1 | 69 |
| 60 | Transforming Growth Factorâ€“Î² Evokes Ca<sup>2+</sup> Waves and Enhances Gene Expression in Human Pulmonary Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 757-764. | 2.9 | 66 |
| 61 | Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, 72, 148-153. | 5.6 | 66 |
| 62 | Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423. | 2.6 | 63 |
| 63 | Mechanical stress-induced mast cell degranulation activates TGF-Î²1 signalling pathway in pulmonary fibrosis. Thorax, 2019, 74, 455-465. | 5.6 | 63 |
| 64 | Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1776-1784. | 6.7 | 61 |
| 65 | Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760. | 6.7 | 61 |
| 66 | Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 3. | 2.0 | 61 |
| 67 | Transient Overexpression of Gremlin Results in Epithelial Activation and Reversible Fibrosis in Rat Lungs. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 870-878. | 2.9 | 60 |
| 68 | Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153. | 5.6 | 60 |
| 69 | Comparison between conventional and "clinical" assessment of experimental lung fibrosis. Journal of Translational Medicine, 2008, 6, 16. | 4.4 | 59 |
| 70 | Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. American Journal of Pathology, 2009, 174, 1683-1691. | 3.8 | 59 |
| 71 | Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078. | 0.8 | 57 |
| 72 | Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal, 2022, 60, 2102571. | 6.7 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Thoracoscopic surgery for tracheal and carinal resection and reconstruction under spontaneous ventilation. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2746-2754. | 0.8 | 54 |
| 74 | Gene Therapy for Pulmonary Diseases. Chest, 2006, 130, 879-884. | 0.8 | 53 |
| 75 | Fibrocytes in pulmonary fibrosis: a brief synopsis. European Respiratory Review, 2013, 22, 552-557. | 7.1 | 52 |
| 76 | The small heatâ€shock protein Î±<scp>B</scp>â€crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis. Journal of Pathology, 2014, 232, 458-472. | 4.5 | 52 |
| 77 | Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1505-1512. | 5.6 | 50 |
| 78 | In VivoRole of Platelet-Derived Growth Factorâ€“BB in Airway Smooth Muscle Proliferation in Mouse Lung. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 566-572. | 2.9 | 49 |
| 79 | Surfactant dysfunction during overexpression of TGF-Î²1 precedes profibrotic lung remodeling in vivo. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L1260-L1271. | 2.9 | 49 |
| 80 | Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2013, 19, 446-452. | 2.6 | 48 |
| 81 | Influenza Promotes Collagen Deposition via Î±vÎ²6 Integrin-mediated Transforming Growth Factor Î² Activation. Journal of Biological Chemistry, 2014, 289, 35246-35263. | 3.4 | 48 |
| 82 | A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249. | 6.7 | 48 |
| 83 | Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. European Respiratory Journal, 2022, 59, 2004538. | 6.7 | 47 |
| 84 | Macitentan reduces progression of TGF-Î²1-induced pulmonary fibrosis andÂpulmonary hypertension. European Respiratory Journal, 2018, 52, 1701857. | 6.7 | 46 |
| 85 | Fibrocytes and fibroblastsâ€”Where are we now. International Journal of Biochemistry and Cell Biology, 2019, 116, 105595. | 2.8 | 46 |
| 86 | Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight, 2022, 7, . | 5.0 | 46 |
| 87 | The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7. | 1.6 | 45 |
| 88 | The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Advances in Therapy, 2019, 36, 3279-3287. | 2.9 | 45 |
| 89 | TRIM33 prevents pulmonary fibrosis by impairing TGF-Î²1 signalling. European Respiratory Journal, 2020, 55, 1901346. | 6.7 | 45 |
| 90 | Connective-Tissue Growth Factor Contributes to TGF-Î²1â€“induced Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 260-270. | 2.9 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers. Respirology, 2015, 20, 1010-1022. | 2.3 | 44 |
| 92 | Lysyl Oxidaseâ€“Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-Î²1â€“induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 461-470. | 2.9 | 44 |
| 93 | Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 450-458. | 2.9 | 42 |
| 94 | Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326. | 2.6 | 42 |
| 95 | What have we learned from basic science studies on idiopathic pulmonary fibrosis?. European Respiratory Review, 2019, 28, 190029. | 7.1 | 42 |
| 96 | Synergistic role of HSP90Î± and HSP90Î² to promote myofibroblast persistence in lung fibrosis. European Respiratory Journal, 2018, 51, 1700386. | 6.7 | 41 |
| 97 | A novel profibrotic mechanism mediated by <scp>TGFÎ²</scp>â€stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. Journal of Pathology, 2015, 236, 384-394. | 4.5 | 40 |
| 98 | Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Medicine, 2015, 13, 176. | 5.5 | 38 |
| 99 | The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators of Inflammation, 2019, 2019, 1-10. | 3.0 | 38 |
| 100 | High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647. | 3.2 | 37 |
| 101 | Pulmonary Microcirculation in Interstitial Lung Disease. Proceedings of the American Thoracic Society, 2011, 8, 516-521. | 3.5 | 34 |
| 102 | Amplification of TGFÎ² Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0158047. | 2.5 | 34 |
| 103 | Animal models of pulmonary fibrosis: how far from effective reality?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L151-L151. | 2.9 | 33 |
| 104 | The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?. European Respiratory Journal, 2018, 51, 1702420. | 6.7 | 33 |
| 105 | Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respiratory Research, 2021, 22, 84. | 3.6 | 33 |
| 106 | Transforming Growth Factor-Î²: Importance in Long-Term Peritoneal Membrane Changes. Peritoneal Dialysis International, 2005, 25, 15-17. | 2.3 | 32 |
| 107 | Current models of pulmonary fibrosis for future drug discovery efforts. Expert Opinion on Drug Discovery, 2020, 15, 931-941. | 5.0 | 31 |
| 108 | Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Annals of the American Thoracic Society, 2017, 14, 1373-1377. | 3.2 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Surfactant dysfunction and alveolar collapse are linked with fibrotic septal wall remodeling in the TGF-Î²1-induced mouse model of pulmonary fibrosis. Laboratory Investigation, 2019, 99, 830-852. | 3.7 | 30 |
| 110 | HSP47: a potential target for fibrotic diseases and implications for therapy. Expert Opinion on Therapeutic Targets, 2021, 25, 49-62. | 3.4 | 30 |
| 111 | ATP stimulates Ca2+-waves and gene expression in cultured human pulmonary fibroblasts. International Journal of Biochemistry and Cell Biology, 2009, 41, 2477-2484. | 2.8 | 29 |
| 112 | Platelet derived growth factor-evoked Ca2+ wave and matrix gene expression through phospholipase C in human pulmonary fibroblast. International Journal of Biochemistry and Cell Biology, 2013, 45, 1516-1524. | 2.8 | 29 |
| 113 | Human mesenchymal stem cells attenuate early damage in a ventilated pig model of acute lung injury. Stem Cell Research, 2016, 17, 25-31. | 0.7 | 29 |
| 114 | Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1702593. | 6.7 | 29 |
| 115 | Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSISÂtrials. European Respiratory Journal, 2019, 54, 1801797. | 6.7 | 28 |
| 116 | Budesonide Enhances Repeated Gene Transfer and Expression in the Lung with Adenoviral Vectors. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 866-872. | 5.6 | 26 |
| 117 | Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 459-467. | 5.6 | 25 |
| 118 | Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329. | 0.8 | 25 |
| 119 | Models of pulmonary fibrosis. Drug Discovery Today: Disease Models, 2006, 3, 243-249. | 1.2 | 24 |
| 120 | Glycosyltransferases and Glycosaminoglycans in Bleomycin and Transforming Growth Factor-Î²1â€“Induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 583-594. | 2.9 | 22 |
| 121 | An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 792-800. | 5.6 | 22 |
| 122 | Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. European Respiratory Journal, 2019, 53, 1801655. | 6.7 | 22 |
| 123 | A Robust Protocol for Decellularized Human Lung Bioink Generation Amenable to 2D and 3D Lung Cell Culture. Cells, 2021, 10, 1538. | 4.1 | 22 |
| 124 | Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research, 2019, 5, 00127-2018. | 2.6 | 21 |
| 125 | How useful is traditional herbal medicine for pulmonary fibrosis?. Respirology, 2009, 14, 1082-1091. | 2.3 | 20 |
| 126 | Adenovirus-Mediated Gene Transfer of TGF-Î²1 to the Renal Glomeruli Leads to Proteinuria. American Journal of Pathology, 2012, 180, 940-951. | 3.8 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respiratory Research, 2022, 23, 54. | 3.6 | 20 |
| 128 | Antifibrotic Role of Î±B-Crystallin Inhibition in Pleural and Subpleural Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 244-252. | 2.9 | 19 |
| 129 | <scp>IL</scp>â€6 mediates <scp>ER</scp> expansion during hyperpolarization of alternatively activated macrophages. Immunology and Cell Biology, 2019, 97, 203-217. | 2.3 | 18 |
| 130 | Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. Current Opinion in Pulmonary Medicine, 2020, 26, 436-442. | 2.6 | 18 |
| 131 | A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322. | 3.6 | 18 |
| 132 | Regulatory T Cells Limit Pneumococcus-Induced Exacerbation of Lung Fibrosis in Mice. Journal of Immunology, 2020, 204, 2429-2438. | 0.8 | 18 |
| 133 | Fibrocytes in chronic lung disease â€“ Facts and controversies. Pulmonary Pharmacology and Therapeutics, 2012, 25, 263-267. | 2.6 | 17 |
| 134 | Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study. Respirology, 2021, 26, 683-689. | 2.3 | 17 |
| 135 | Vascular Repair and Regeneration as a Therapeutic Target for Pulmonary Arterial Hypertension. Respiration, 2013, 85, 355-364. | 2.6 | 16 |
| 136 | Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. European Respiratory Journal, 2016, 48, 1524-1526. | 6.7 | 16 |
| 137 | Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 127-137. | 1.9 | 16 |
| 138 | Therapeutic targets and early stage clinical trials for pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2019, 28, 19-28. | 4.1 | 16 |
| 139 | Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27. | 3.2 | 16 |
| 140 | Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141. | 0.5 | 15 |
| 141 | Clonally selected primitive endothelial cells promote occlusive pulmonary arteriopathy and severe pulmonary hypertension in rats exposed to chronic hypoxia. Scientific Reports, 2020, 10, 1136. | 3.3 | 15 |
| 142 | Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259. | 5.6 | 15 |
| 143 | The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. Advances in Therapy, 2022, 39, 3881-3895. | 2.9 | 15 |
| 144 | New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. Expert Review of Respiratory Medicine, 2013, 7, 465-478. | 2.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895. | 0.8 | 14 |
| 146 | A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis. European Respiratory Journal, 2019, 53, 1900329. | 6.7 | 14 |
| 147 | The transforming growth factor-beta (TGF-Î²) family and pulmonary fibrosis. Drug Discovery Today Disease Mechanisms, 2006, 3, 99-103. | 0.8 | 13 |
| 148 | Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs: the Investigational Drugs Journal, 2010, 13, 332-45. | 0.7 | 13 |
| 149 | Pulmonary and Cardiac Function in Asymptomatic Obese Subjects and Changes following a Structured Weight Reduction Program: A Prospective Observational Study. PLoS ONE, 2014, 9, e107480. | 2.5 | 12 |
| 150 | Fibrocytes and Progression of Fibrotic Lung Disease. Ready for Showtime?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1338-1339. | 5.6 | 12 |
| 151 | Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest, 2020, 158, 2270-2274. | 0.8 | 12 |
| 152 | Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644. | 2.3 | 12 |
| 153 | Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. International Journal of Molecular Sciences, 2021, 22, 9316. | 4.1 | 11 |
| 154 | Identification of RARRES1 as a core regulator in liver fibrosis. Journal of Molecular Medicine, 2012, 90, 1439-1447. | 3.9 | 10 |
| 155 | FK506-Binding Protein 13 Expression Is Upregulated in Interstitial Lung Disease and Correlated with Clinical Severity. A Potentially Protective Role. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 235-246. | 2.9 | 10 |
| 156 | The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. European Respiratory Journal, 2021, 57, 2100079. | 6.7 | 10 |
| 157 | Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. Thorax, 2021, 76, 895-906. | 5.6 | 10 |
| 158 | Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092. | 5.6 | 10 |
| 159 | FGF19 is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2022, , . | 2.9 | 10 |
| 160 | Treating IPFâ€”all or nothing? A PROâ€CON debate. Respirology, 2009, 14, 1072-1081. | 2.3 | 9 |
| 161 | Viruses and Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1583-1584. | 5.6 | 9 |
| 162 | Guideline-directed management of COVID-19: Do's and Don'ts. European Respiratory Journal, 2021, 57, 2100753. | 6.7 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Abrogation of mesenchyme-specific TGF-Î² signaling results in lung malformation with prenatal pulmonary cysts in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L1158-L1168. | 2.9 | 9 |
| 164 | R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life. European Respiratory Journal, 2022, 59, 2100917. | 6.7 | 9 |
| 165 | Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage. European Respiratory Journal, 2017, 49, 1700811. | 6.7 | 8 |
| 166 | Idiopathic pulmonary fibrosis: idiopathic no more?. Lancet Respiratory Medicine,the, 2018, 6, 84-85. | 10.7 | 8 |
| 167 | Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243. | 0.5 | 8 |
| 168 | Role of the COX2-PGE<sub>2</sub> axis in S. pneumoniae-induced exacerbation of experimental fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L377-L392. | 2.9 | 8 |
| 169 | Mouse Models of Lung Fibrosis. Methods in Molecular Biology, 2021, 2299, 291-321. | 0.9 | 8 |
| 170 | Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644. | 2.6 | 8 |
| 171 | Rapid detection of circulating fibrocytes by flowcytometry in idiopathic pulmonary fibrosis. Annals of Thoracic Medicine, 2015, 10, 279-83. | 1.8 | 8 |
| 172 | Update on models of pulmonary fibrosis therapy for preclinical drug research. Expert Opinion on Drug Discovery, 2009, 4, 939-946. | 5.0 | 7 |
| 173 | The Role of Follow-up Evaluation in the Diagnostic Algorithm of Idiopathic Interstitial Pneumonia: A Retrospective Study. Scientific Reports, 2019, 9, 6452. | 3.3 | 7 |
| 174 | A cross-sectional evaluation of the idiopathic pulmonary fibrosis patient satisfaction and quality of life with a care coordinator. Journal of Thoracic Disease, 2019, 11, 5547-5556. | 1.4 | 7 |
| 175 | Have advanced research technologies made real impact on respiratory medicine?. Respirology, 2010, 15, 876-880. | 2.3 | 6 |
| 176 | Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution â€“ Authors' reply. Lancet Respiratory Medicine,the, 2016, 4, e48. | 10.7 | 6 |
| 177 | Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what'sÂin a name?. European Respiratory Journal, 2019, 53, 1801939. | 6.7 | 6 |
| 178 | Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 58, 2100172. | 6.7 | 6 |
| 179 | Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications. Expert Opinion on Therapeutic Targets, 2021, 25, 939-948. | 3.4 | 6 |
| 180 | B Cells Are Not Involved in the Regulation of Adenoviral TGF-Î²1â€“ or Bleomycin-Induced Lung Fibrosis in Mice. Journal of Immunology, 2022, 208, 1259-1271. | 0.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Guidance production before evidence generation for critical issues: the example of COVID-19. European Respiratory Review, 2020, 29, 200310. | 7.1 | 5 |
| 182 | Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084. | 3.2 | 5 |
| 183 | Making the case for causality: what role do lung microbiota play in idiopathic pulmonary fibrosis?. European Respiratory Journal, 2020, 55, 2000318. | 6.7 | 5 |
| 184 | Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202. | 3.6 | 5 |
| 185 | Lung surgery in interstitial lung disease-a safe and useful procedure?. Journal of Thoracic Disease, 2013, 5, 375-7. | 1.4 | 5 |
| 186 | Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 962-970. | 3.2 | 5 |
| 187 | Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respiratory Medicine, 2022, 195, 106792. | 2.9 | 5 |
| 188 | Drug development for chronic lung disease â€•Mission impossible?. Respirology, 2015, 20, 13-14. | 2.3 | 4 |
| 189 | Pathways to Precision Medicine in Idiopathic Pulmonary Fibrosis. Time to Relax?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1315-1317. | 5.6 | 4 |
| 190 | Abnormal extracellular matrix: The common thread of diseases progression in fibrosis?. Arthritis and Rheumatology, 2016, 68, n/a-n/a. | 5.6 | 4 |
| 191 | Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 355-357. | 5.6 | 4 |
| 192 | An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases. Annals of the American Thoracic Society, 2017, 14, 1239-1247. | 3.2 | 4 |
| 193 | Radiological diagnosis of interstitial lung disease: is it all about pattern recognition?. European Respiratory Journal, 2018, 52, 1801321. | 6.7 | 4 |
| 194 | Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society, 2021, 18, 1661-1668. | 3.2 | 4 |
| 195 | Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. Journal of Rheumatology, 2021, 48, 1427-1434. | 2.0 | 4 |
| 196 | Clinical relevance of rheumatoid factor and antiâ€citrullinated peptides in fibrotic interstitial lung disease. Respirology, 0, , . | 2.3 | 4 |
| 197 | Strategies targeting fibrosis in pulmonary disease. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 389-394. | 0.5 | 3 |
| 198 | Identification of Fibrocytes in Peripheral Blood. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1279-1280. | 5.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | A Switch in TGF-Î² Signaling Explains Contradictory Findings in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 157-159. | 5.6 | 3 |
| 200 | Adenoviral vector-mediated GM-CSF gene transfer improves anti-mycobacterial immunity in mice â€“ role of regulatory T cells. Immunobiology, 2018, 223, 331-341. | 1.9 | 3 |
| 201 | Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155. | 0.5 | 3 |
| 202 | Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 214-225. | 0.5 | 3 |
| 203 | The evolution of the European Respiratory Journal: weathering the publishing pandemic. European Respiratory Journal, 2021, 57, 2100084. | 6.7 | 3 |
| 204 | Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil. , 2019, , . | | 3 |
| 205 | Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722. | 2.9 | 3 |
| 206 | Transdiaphragmatic liver herniation mimicking pulmonary nodule. European Journal of Radiology Extra, 2003, 46, 17-20. | 0.1 | 2 |
| 207 | Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. Thorax, 2016, 71, 399-400. | 5.6 | 2 |
| 208 | Personalised medicine for IPF: getting closer, but not there yet. Lancet Respiratory Medicine,the, 2017, 5, 836-837. | 10.7 | 2 |
| 209 | Molecular breath analysis for IPF: Can we make a few breaths count?. Respirology, 2019, 24, 404-405. | 2.3 | 2 |
| 210 | Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 226-228. | 0.5 | 2 |
| 211 | Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough. Respiratory Medicine, 2020, 170, 106067. | 2.9 | 2 |
| 212 | Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?. European Respiratory Journal, 2020, 55, 2000590. | 6.7 | 2 |
| 213 | The Extracellular Matrix-Cell Interaction in ILD. , 2022, , 126-134. | | 2 |
| 214 | Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 863-867. | 3.2 | 2 |
| 215 | Clinical trials in idiopathic pulmonary fibrosis: update and perspectives. Clinical Investigation, 2011, 1, 1669-1680. | 0.0 | 1 |
| 216 | Interstitial lung disease: time to rethink the snapshot diagnosis?. Thorax, 2016, 71, 5-7. | 5.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Pulmonary fibrosis: â€œidiopathicâ€•is not â€œcryptogenicâ€• European Respiratory Journal, 2019, 53, 1900400. | 6.7 | 1 |
| 218 | EFFECT OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING ILDS AND PRESERVED LUNG FUNCTION AT BASELINE: FURTHER ANALYSES OF THE INBUILD TRIAL. Chest, 2020, 158, A1051-A1052. | 0.8 | 1 |
| 219 | Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution?. European Respiratory Journal, 2021, 57, 2100691. | 6.7 | 1 |
| 220 | The evolution of the European Respiratory Journal: adapting in an era of change. European Respiratory Journal, 2022, 59, 2200037. | 6.7 | 1 |
| 221 | Transforming Growth Factor-β Peptide Signaling in Lung Development: Bronchopulmonary Dysplasia, Lung Fibrosis and Emphysema. Current Respiratory Medicine Reviews, 2005, 1, 325-329. | 0.2 | 0 |
| 222 | TGFÎ² and Smad3 link inflammation to progressive fibrosis. International Congress Series, 2007, 1302, 103-113. | 0.2 | 0 |
| 223 | Targeting fibrosis in respiratory lung disease. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 97-100. | 0.5 | 0 |
| 224 | The use of small animal imaging in respiratory disease drug discovery. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 81-85. | 0.5 | 0 |
| 225 | Respirology yearâ€inâ€review 2008: Basic science. Respirology, 2009, 14, 318-326. | 2.3 | 0 |
| 226 | Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?. Current Pulmonology Reports, 2015, 4, 125-129. | 1.3 | 0 |
| 227 | A 43-year-old man with cough, expectoration and recurrent wheezing. Journal of Thoracic Disease, 2016, 8, 3468-3477. | 1.4 | 0 |
| 228 | Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of GAP Stage at Baseline in the INPULSIS Trials. Chest, 2016, 150, 540A. | 0.8 | 0 |
| 229 | A female patient with recurrent lung lesion and hilar lymphadenopathy. Journal of Thoracic Disease, 2017, 9, 1858-1863. | 1.4 | 0 |
| 230 | Turning thirty: evolution but not revolution at the ERJ. European Respiratory Journal, 2018, 51, 1702594. | 6.7 | 0 |
| 231 | Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258. | 0.5 | 0 |
| 232 | The Role of Mast Cells in the Pathophysiology of Pulmonary Fibrosis. Molecular and Translational Medicine, 2019, , 135-173. | 0.4 | 0 |
| 233 | Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 25-30. | 0.5 | 0 |
| 234 | EFFICACY AND SAFETY OF NINTEDANIB IN US/CANADIAN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: FURTHER ANALYSES OF THE INBUILD TRIAL. Chest, 2020, 158, A2613-A2615. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | The evolution of the European Respiratory Journal: ready for the new decade!. European Respiratory Journal, 2020, 55, 1902503. | 6.7 | 0 |
| 236 | Interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 93-96. | 0.5 | 0 |
| 237 | Fibrocytes in Interstitial Lung Disease. , 2011, , 131-141. | | 0 |
| 238 | Idiopathische Lungenfibrose. , 2016, , 127-141. | | 0 |